Advanced Search

Home > Journals > Minerva Ginecologica > Past Issues > Minerva Ginecologica 2012 February;64(1) > Minerva Ginecologica 2012 February;64(1):41-52



A Journal on Obstetrics and Gynecology

Indexed/Abstracted in: EMBASE, PubMed/MEDLINE, Scopus, Emerging Sources Citation Index

Frequency: Bi-Monthly

ISSN 0026-4784

Online ISSN 1827-1650


Minerva Ginecologica 2012 February;64(1):41-52


Association of E2v/dng as contraceptive choice for a better quality of life of women

Nappi R. E.

Centro di Ricerca per la Procreazione Medicalmente Assistita e Servizio di Endocrinologia Ginecologica e della Menopausa, Clinica Ostetrica e Ginecologica IRCCS, Fondazione S. Matteo, Università degli Studi di Pavia, Pavia, Italia

The association of estradiol valerate/dienogest (E2V/DNG) is an innovative contraceptive choice with relevant consequences for quality of life of women at all ages. Klaira® (E2V/DNG) combines the use of natural estradiol in a dynamic dosing regimen with a progestin very similar to natural progesterone but with very potent antiproliferative action at the endometrial level. The high contraceptive efficacy of E2V/DNG is associated with a good menstrual cycle control which leads to a novel therapeutic indication in heavy menstrual bleeding. The mild hemostatic and metabolic impact is highly important for women over 35 years, especially when painful syndromes are present (dysmenorrhea and headache), with potential benefits of E2V/DNG, even though the current contraindications of hormonal contraception with ethynilestradiol are still present. In addition, good tolerability and the evidence of beneficial effects on sexual function make E2V/DNG a contraceptive hormonal method with a favourable profile in term of psychophysical well being of women.

language: English


top of page